Biotech Values

[DewDiligence]

[GSK’s CEO, Andrew] Witty is diversifying the group to reduce reliance on "white pills in Western markets", the part of the business most vulnerable to generic competition and price cuts. The result is an increased focus on consumer healthcare and emerging markets.

http://www.reuters.com/article/2011/07/26/glaxosmithkline-idUSL6E7IQ04W20110726

I think Witty’s pet phrase quoted above is dumb, but his determination to focus on branded generics in emerging market is necessary for GSK to grow sales and earnings.